{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T13:17:01Z","timestamp":1783603021398,"version":"3.55.0"},"reference-count":70,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>Prostate cancer (PC) care has undergone a significant transformation in the past decade, leading to unprecedented survival outcomes, particularly for patients with newly diagnosed metastatic disease. However, there is a sizable gap in efficacy and toxicity between PC clinical trial populations and those in the real world. Additionally, there has been a persistent lack of adoption of modern PC therapies, particularly in the metastatic hormone-sensitive PC setting. A key reason for slow adoption, despite robust survival data, is that clinicians feel that their patients are not adequately reflected in clinical trial populations. Key populations that have been underrepresented in PC trials include older adults, individuals with comorbidities, rural populations, and people of non-European ancestry. The lack of these patient populations in modern PC clinical trials impacts the broader adoption of modern therapies, limits our understanding of real-world effectiveness and adverse effect profiles, and hinders the discovery of ancestry-related clinical or pharmacogenomic biomarkers. In this review, we propose multiple strategies to help shape clinical trial populations to better reflect the patients we see in the real world, particularly in later-phase studies.<\/jats:p>","DOI":"10.6004\/jnccn.2026.7002","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:32:47Z","timestamp":1779309167000},"source":"Crossref","is-referenced-by-count":0,"title":["Real-World Representation in Prostate Cancer Clinical Trials: Needs and Opportunities"],"prefix":"10.6004","volume":"24","author":[{"given":"Hannah D.","family":"McManus","sequence":"first","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, NC"},{"name":"Duke Cancer Institute, Center for Prostate and Urologic Cancers, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"George","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, NC"},{"name":"Duke Cancer Institute, Center for Prostate and Urologic Cancers, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey W.","family":"Shevach","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, NC"},{"name":"Duke Cancer Institute, Center for Prostate and Urologic Cancers, Durham, NC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"JNCI Cancer Spectr","first-page":"pkaf018","article-title":"Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer","volume":"9","author":"Axeen S","year":"2025","unstructured":"Axeen S, Chen AJ, Lakdawalla DN,  Do trial benefits predict real-world gains in metastatic castration resistant prostate cancer. JNCI Cancer Spectr 2025;9:pkaf018."},{"key":"B2","series-title":"Prostate Cancer Prostatic Dis","first-page":"756","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George DJ","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H,  Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-na\u00efve patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2024;27:756\u2013764."},{"key":"B3","series-title":"JCO Oncol Pract","first-page":"1174","article-title":"Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the United States from 2017 to 2023","volume":"21","author":"Raval AD","year":"2025","unstructured":"Raval AD, Lunacsek O, Korn MJ,  Real-world evidence of combination therapy use in metastatic hormone-sensitive prostate cancer in the United States from 2017 to 2023. JCO Oncol Pract 2025;21:1174\u20131184."},{"key":"B4","series-title":"MMWR Morb Mortal Wkly Rep","first-page":"1473","article-title":"Prostate cancer incidence and survival, by stage and race\/ethnicity \u2013 United States, 2001\u20132017","volume":"69","author":"Siegel DA","year":"2020","unstructured":"Siegel DA, O\u2019Neil ME, Richards TB,  Prostate cancer incidence and survival, by stage and race\/ethnicity \u2013 United States, 2001\u20132017. MMWR Morb Mortal Wkly Rep 2020;69:1473\u20131480."},{"key":"B5","series-title":"Clin Genitourin Cancer","first-page":"e467","article-title":"Examining exclusion criteria in advanced prostate cancer clinical trials: an assessment of recommendations from the American Society of Clinical Oncology and Friends of Cancer Research","volume":"21","author":"Ebrahimi H","year":"2023","unstructured":"Ebrahimi H, Castro DV, Feng MI,  Examining exclusion criteria in advanced prostate cancer clinical trials: an assessment of recommendations from the American Society of Clinical Oncology and Friends of Cancer Research. Clin Genitourin Cancer 2023;21:e467\u2013473."},{"key":"B6","series-title":"JAMA Oncol","first-page":"180","article-title":"Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis","volume":"9","author":"Riaz IB","year":"2023","unstructured":"Riaz IB, Islam M, Ikram W,  Disparities in the inclusion of racial and ethnic minority groups and older adults in prostate cancer clinical trials: a meta-analysis. JAMA Oncol 2023;9:180\u2013187."},{"key":"B7","series-title":"J Clin Oncol","first-page":"2036","article-title":"Under-representation of older adults in cancer registration trials: known problem, little progress","volume":"30","author":"Scher KS","year":"2012","unstructured":"Scher KS, Hurria A. Under-representation of older adults in cancer registration trials: known problem, little progress. J Clin Oncol 2012;30:2036\u20132038."},{"key":"B8","series-title":"Eur Urol Oncol","first-page":"14","article-title":"Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201creal world\u201d? A systematic review","volume":"7","author":"Dodkins J","year":"2024","unstructured":"Dodkins J, Nossiter J, Cook A,  Does research from clinical trials in metastatic hormone-sensitive prostate cancer treatment translate into access to treatments for patients in the \u201creal world\u201d? A systematic review. Eur Urol Oncol 2024;7:14\u201324."},{"key":"B9","series-title":"JAMA Netw Open","first-page":"e2448707","article-title":"Physician reasons for or against treatment intensification in patients with metastatic prostate cancer","volume":"7","author":"Agarwal N","year":"2024","unstructured":"Agarwal N, George DJ, Klaassen Z,  Physician reasons for or against treatment intensification in patients with metastatic prostate cancer. JAMA Netw Open 2024;7:e2448707."},{"key":"B10","series-title":"JAMA Netw Open","first-page":"e2535728","article-title":"Barriers and facilitators of treatment intensification in metastatic castration-sensitive prostate cancer","volume":"8","author":"Loeb S","year":"2025","unstructured":"Loeb S, Agarwal N, El-Chaar N,  Barriers and facilitators of treatment intensification in metastatic castration-sensitive prostate cancer. JAMA Netw Open 2025;8:e2535728."},{"key":"B11","series-title":"Cancer","first-page":"e70070","article-title":"Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: a population-based study","volume":"131","author":"Nguyen DD","year":"2025","unstructured":"Nguyen DD, Satkunasivam R, Aminoltejari K,  Association of patient and physician characteristics with androgen-deprivation-therapy intensification in patients with de novo hormone-sensitive metastatic prostate cancer: a population-based study. Cancer 2025;131:e70070."},{"key":"B12","series-title":"BJU Int","first-page":"408","article-title":"Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review","volume":"135","author":"Raval AD","year":"2025","unstructured":"Raval AD, Chen S, Littleton N,  Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review. BJU Int 2025;135:408\u2013421."},{"key":"B13","series-title":"J Clin Oncol","first-page":"3737","article-title":"Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement","volume":"35","author":"Kim ES","year":"2017","unstructured":"Kim ES, Bruinooge SS, Roberts S,  Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research joint research statement. J Clin Oncol 2017;35:3737\u20133744."},{"key":"B14","series-title":"Clin Cancer Res","first-page":"2424","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research performance status work group","volume":"27","author":"Magnuson A","year":"2021","unstructured":"Magnuson A, Bruinooge SS, Singh H,  Modernizing clinical trial eligibility criteria: recommendations of the ASCO-Friends of Cancer Research performance status work group. Clin Cancer Res 2021;27:2424\u20132429."},{"key":"B15","series-title":"Lancet Oncol","first-page":"117","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen PL","year":"2013","unstructured":"Kellokumpu-Lehtinen PL, Harmenberg U, Joensuu T,  2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol 2013;14:117\u2013124."},{"key":"B16","series-title":"JAMA Oncol","first-page":"1629","article-title":"Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard S","year":"2023","unstructured":"Oudard S, Ratta R, Voog E,  Biweekly vs triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial. JAMA Oncol 2023;9:1629\u20131638."},{"key":"B17","series-title":"Lancet","first-page":"1749","article-title":"Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial","volume":"377","author":"Seymour MT","year":"2011","unstructured":"Seymour MT, Thompson LC, Wasan HS,  Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;377:1749\u20131759."},{"key":"B18","series-title":"Eur Urol Oncol","first-page":"1376","article-title":"A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer","volume":"7","author":"Boerrigter E","year":"2024","unstructured":"Boerrigter E, Overbeek JK, Benoist GE,  A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer. Eur Urol Oncol 2024;7:1376\u20131383."},{"key":"B19","series-title":"MMWR Surveill Summ","first-page":"1","article-title":"Invasive cancer incidence, 2004\u20132013, and deaths, 2006\u20132015, in nonmetropolitan and metropolitan counties \u2013 United States","volume":"66","author":"Henley SJ","year":"2017","unstructured":"Henley SJ, Anderson RN, Thomas CC,  Invasive cancer incidence, 2004\u20132013, and deaths, 2006\u20132015, in nonmetropolitan and metropolitan counties \u2013 United States. MMWR Surveill Summ 2017;66:1\u201313."},{"key":"B20","series-title":"Cancer Med","first-page":"1490","article-title":"Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah","volume":"7","author":"Hashibe M","year":"2018","unstructured":"Hashibe M, Kirchhoff AC, Kepka D,  Disparities in cancer survival and incidence by metropolitan versus rural residence in Utah. Cancer Med 2018;7:1490\u20131497."},{"key":"B21","series-title":"J Natl Compr Canc Netw","first-page":"e247094","article-title":"Rurality status and cardiovascular events\/survival in older men with prostate cancer","volume":"23","author":"Jiang S","year":"2025","unstructured":"Jiang S, Patel V, Stabellini N,  Rurality status and cardiovascular events\/survival in older men with prostate cancer. J Natl Compr Canc Netw 2025;23:e247094."},{"key":"B22","series-title":"JAMA Netw Open","first-page":"e181235","article-title":"Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials","volume":"1","author":"Unger JM","year":"2018","unstructured":"Unger JM, Moseley A, Symington B,  Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open 2018;1:e181235."},{"key":"B23","series-title":"J Urol","first-page":"108","article-title":"Under treatment of prostate cancer in rural locations","volume":"203","author":"Maganty A","year":"2020","unstructured":"Maganty A, Sabik LM, Sun Z,  Under treatment of prostate cancer in rural locations. J Urol 2020;203:108\u2013114."},{"key":"B24","series-title":"JCO Oncol Pract","first-page":"1109","article-title":"Differences in rural versus urban patients with prostate cancer in diagnosis and treatment: an analysis of a population-based cohort","volume":"20","author":"Shen X","year":"2024","unstructured":"Shen X, Kane K, Katz AJ,  Differences in rural versus urban patients with prostate cancer in diagnosis and treatment: an analysis of a population-based cohort. JCO Oncol Pract 2024;20:1109\u20131114."},{"key":"B25","series-title":"JNCI Cancer Spectr","first-page":"pkab082","article-title":"Real-world use of androgen-deprivation therapy: intensification among older Canadian men with de novo metastatic prostate cancer","volume":"5","author":"Wallis CJD","year":"2021","unstructured":"Wallis CJD, Malone S, Cagiannos I,  Real-world use of androgen-deprivation therapy: intensification among older Canadian men with de novo metastatic prostate cancer. JNCI Cancer Spectr 2021;5:pkab082."},{"key":"B26","series-title":"Intern Med J","first-page":"1339","article-title":"Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer","volume":"52","author":"Azad AA","year":"2022","unstructured":"Azad AA, Tran B, Davis ID,  Predictors of real-world utilisation of docetaxel combined with androgen deprivation therapy in metastatic hormone-sensitive prostate cancer. Intern Med J 2022;52:1339\u20131346."},{"key":"B27","series-title":"JCO Oncol Pract","first-page":"427","article-title":"State of geographic access to cancer treatment trials in the United States: are studies located where patients live?","volume":"21","author":"Kirkwood MK","year":"2025","unstructured":"Kirkwood MK, Schenkel C, Hinshaw DC,  State of geographic access to cancer treatment trials in the United States: are studies located where patients live? JCO Oncol Pract 2025;21:427\u2013437."},{"key":"B28","series-title":"JAMA Intern Med","first-page":"293","article-title":"Geographic accessibility to clinical trials for advanced cancer in the United States","volume":"175","author":"Galsky MD","year":"2015","unstructured":"Galsky MD, Stensland KD, McBride RB,  Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med 2015;175:293\u2013295."},{"key":"B29","series-title":"CA Cancer J Clin","first-page":"341","article-title":"Cancer in rural America: improving access to clinical trials and quality of oncologic care","volume":"75","author":"Unger JM","year":"2025","unstructured":"Unger JM, McAneny BL, Osarogiagbon RU. Cancer in rural America: improving access to clinical trials and quality of oncologic care. CA Cancer J Clin 2025;75:341\u2013361."},{"key":"B30","series-title":"JAMA Netw Open","first-page":"e250778","article-title":"Health care contact days for older adults enrolled in cancer clinical trials","volume":"8","author":"Gupta A","year":"2025","unstructured":"Gupta A, Till C, Vaidya R,  Health care contact days for older adults enrolled in cancer clinical trials. JAMA Netw Open 2025;8:e250778."},{"key":"B31","series-title":"JAMA Netw Open","first-page":"e248739","article-title":"Barriers to clinical trial implementation among community care centers","volume":"7","author":"Ebrahimi H","year":"2024","unstructured":"Ebrahimi H, Megally S, Plotkin E,  Barriers to clinical trial implementation among community care centers. JAMA Netw Open 2024;7:e248739."},{"key":"B32","series-title":"J Oncol Pract","first-page":"172","article-title":"Barriers to recruitment of rural patients in cancer clinical trials","volume":"7","author":"Virani S","year":"2011","unstructured":"Virani S, Burke L, Remick SC, Abraham J. Barriers to recruitment of rural patients in cancer clinical trials. J Oncol Pract 2011;7:172\u2013177."},{"key":"B33","series-title":"J Rural Health","first-page":"e70029","article-title":"Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER-Medicare data","volume":"41","author":"Chang Esther CP","year":"2025","unstructured":"Chang Esther CP, Huang D, Lloyd S,  Risks of adverse health outcomes among older rural prostate cancer survivors in the SEER-Medicare data. J Rural Health 2025;41:e70029."},{"key":"B34","series-title":"J Natl Cancer Inst","first-page":"1127","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai LY","year":"2022","unstructured":"Lai LY, Oerline MK, Caram MEV,  Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer. J Natl Cancer Inst 2022;114:1127\u20131134."},{"key":"B35","series-title":"Clin Genitourin Cancer","first-page":"e645","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli R","year":"2018","unstructured":"Iacovelli R, Ciccarese C, Bria E,  The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer. Clin Genitourin Cancer 2018;16:e645\u2013653."},{"key":"B36","series-title":"J Am Coll Cardiol","first-page":"315","article-title":"Geographic disparities in access to cardiologists in the United States","volume":"84","author":"Kim JH","year":"2024","unstructured":"Kim JH, Cisneros T, Nguyen A,  Geographic disparities in access to cardiologists in the United States. J Am Coll Cardiol 2024;84:315\u2013316."},{"key":"B37","series-title":"Circulation","first-page":"2594","article-title":"Representation of patients with cardiovascular disease in pivotal cancer clinical trials","volume":"139","author":"Bonsu J","year":"2019","unstructured":"Bonsu J, Charles L, Guha A,  Representation of patients with cardiovascular disease in pivotal cancer clinical trials. Circulation 2019;139:2594\u20132596."},{"key":"B38","series-title":"JCO Oncol Pract","first-page":"422","article-title":"Closing the rural cancer care gap: three institutional approaches","volume":"16","author":"Levit LA","year":"2020","unstructured":"Levit LA, Byatt L, Lyss AP,  Closing the rural cancer care gap: three institutional approaches. JCO Oncol Pract 2020;16:422\u2013430."},{"key":"B39","series-title":"Cancer","first-page":"1193","article-title":"A call to action to advance patient- focused and decentralized clinical trials","volume":"130","author":"Harvey RD","year":"2024","unstructured":"Harvey RD, Miller TM, Hurley PA,  A call to action to advance patient- focused and decentralized clinical trials. Cancer 2024;130:1193\u20131203."},{"key":"B40","article-title":"Conducting clinical trials with decentralized elements","year":"2025","unstructured":"U.S. Food and Drug Administration. Conducting clinical trials with decentralized elements. Accessed June 27, 2025. Available at: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/conducting-clinical-trials-decentralized-elements"},{"key":"B41","series-title":"Contemp Clin Trials Commun","first-page":"101366","article-title":"The impact of internet connectivity when conducting a virtual clinical trial with participants living in rural areas","volume":"42","author":"Holland DE","year":"2024","unstructured":"Holland DE, Vanderboom CE, Mandrekar J,  The impact of internet connectivity when conducting a virtual clinical trial with participants living in rural areas. Contemp Clin Trials Commun 2024;42:101366."},{"key":"B42","series-title":"Nature","first-page":"340","article-title":"Genomic data in the All of Us Research Program","volume":"627","year":"2024","unstructured":"All of Us Research Program Genomics Investigators. Genomic data in the All of Us Research Program. Nature 2024;627:340\u2013346."},{"key":"B43","series-title":"Nat Genet","first-page":"904","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price AL","year":"2006","unstructured":"Price AL, Patterson NJ, Plenge RM,  Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006;38:904\u2013909."},{"key":"B44","series-title":"CA Cancer J Clin","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel RL","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN,  Cancer statistics, 2025. CA Cancer J Clin 2025;75:10\u201345."},{"key":"B45","series-title":"Eur Urol Oncol","first-page":"18","article-title":"Prostate cancer racial disparities: a systematic review by the Prostate Cancer Foundation panel","volume":"5","author":"Mahal BA","year":"2022","unstructured":"Mahal BA, Gerke T, Awasthi S,  Prostate cancer racial disparities: a systematic review by the Prostate Cancer Foundation panel. Eur Urol Oncol 2022;5:18\u201329."},{"key":"B46","series-title":"Nat Genet","first-page":"2093","article-title":"Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa","volume":"56","author":"Janivara R","year":"2024","unstructured":"Janivara R, Chen WC, Hazra U,  Heterogeneous genetic architectures of prostate cancer susceptibility in sub-Saharan Africa. Nat Genet 2024;56:2093\u20132103."},{"key":"B47","series-title":"J Natl Cancer Inst","first-page":"djx084","article-title":"Two novel susceptibility loci for prostate cancer in men of African ancestry","volume":"109","author":"Conti DV","year":"2017","unstructured":"Conti DV, Wang K, Sheng X,  Two novel susceptibility loci for prostate cancer in men of African ancestry. J Natl Cancer Inst 2017;109:djx084."},{"key":"B48","series-title":"J Clin Oncol","first-page":"403","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi S","year":"2019","unstructured":"Halabi S, Dutta S, Tangen CM,  Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2019;37:403\u2013410."},{"key":"B49","series-title":"Prostate Cancer Prostatic Dis","first-page":"517","article-title":"Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry","volume":"23","author":"Sartor O","year":"2020","unstructured":"Sartor O, Armstrong AJ, Ahaghotu C,  Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. Prostate Cancer Prostatic Dis 2020;23:517\u2013526."},{"key":"B50","series-title":"J Urol","first-page":"81","article-title":"Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies","volume":"176","author":"Halabi S","year":"2006","unstructured":"Halabi S, Vogelzang NJ, Ou SS,  Clinical outcomes by age in men with hormone refractory prostate cancer: a pooled analysis of 8 Cancer and Leukemia Group B (CALGB) studies. J Urol 2006;176:81\u201386."},{"key":"B51","series-title":"JAMA Netw Open","first-page":"e2139769","article-title":"Comparison of response to definitive radiotherapy for localized prostate cancer in Black and White men: a meta-analysis","volume":"4","author":"Ma TM","year":"2021","unstructured":"Ma TM, Romero T, Nickols NG,  Comparison of response to definitive radiotherapy for localized prostate cancer in Black and White men: a meta-analysis. JAMA Netw Open 2021;4:e2139769."},{"key":"B52","series-title":"Prostate Cancer Prostatic Dis","first-page":"524","article-title":"Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer","volume":"25","author":"George DJ","year":"2022","unstructured":"George DJ, Ramaswamy K, Huang A,  Survival by race in men with chemotherapy-naive enzalutamide- or abiraterone-treated metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2022;25:524\u2013530."},{"key":"B53","series-title":"JAMA Netw Open","first-page":"e2142093","article-title":"Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar M","year":"2022","unstructured":"Marar M, Long Q, Mamtani R,  Outcomes among African American and non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093."},{"key":"B54","series-title":"J Natl Compr Canc Netw","first-page":"733","article-title":"Impact of Asian race on prognosis in de novo metastatic prostate cancer","volume":"21","author":"Ni X","year":"2023","unstructured":"Ni X, Luu M, Ma W,  Impact of Asian race on prognosis in de novo metastatic prostate cancer. J Natl Compr Canc Netw 2023;21:733\u2013741.e3."},{"key":"B55","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1374","article-title":"Diversity of enrollment in prostate cancer clinical trials: current status and future directions","volume":"29","author":"Rencsok EM","year":"2020","unstructured":"Rencsok EM, Bazzi LA, McKay RR,  Diversity of enrollment in prostate cancer clinical trials: current status and future directions. Cancer Epidemiol Biomarkers Prev 2020;29:1374\u20131380."},{"key":"B56","series-title":"Cell","first-page":"1074","article-title":"A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer","volume":"154","author":"Chang KH","year":"2013","unstructured":"Chang KH, Li R, Kuri B,  A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell 2013;154:1074\u20131084."},{"key":"B57","series-title":"J Clin Invest","first-page":"3333","article-title":"HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer","volume":"128","author":"Alyamani M","year":"2018","unstructured":"Alyamani M, Emamekhoo H, Park S,  HSD3B1(1245A>C) variant regulates dueling abiraterone metabolite effects in prostate cancer. J Clin Invest 2018;128:3333\u20133340."},{"key":"B58","series-title":"JAMA Netw Open","first-page":"e242976","article-title":"Adrenal-permissive germline HSD3B1 allele and prostate cancer outcomes","volume":"7","author":"McKay RR","year":"2024","unstructured":"McKay RR, Nelson TJ, Pagadala MS,  Adrenal-permissive germline HSD3B1 allele and prostate cancer outcomes. JAMA Netw Open 2024;7:e242976."},{"key":"B59","series-title":"Nature","first-page":"92","article-title":"A genomic mutational constraint map using variation in 76,156 human genomes","volume":"625","author":"Chen S","year":"2024","unstructured":"Chen S, Francioli LC, Goodrich JK,  A genomic mutational constraint map using variation in 76,156 human genomes. Nature 2024;625:92\u2013100."},{"key":"B60","series-title":"J Clin Oncol","first-page":"e17076","article-title":"Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study","volume":"43(Suppl)","author":"George DJ","year":"2025","unstructured":"George DJ, Howard L, Halabi S,  Predictive associations between serum dehydroepiandrosterone sulfate (DHEAS) and race among patients (pts) treated with apalutamide (apa), abiraterone acetate (AA) plus prednisone (P) in the PANTHER study. J Clin Oncol 2025;43(Suppl):Abstract e17076."},{"key":"B61","series-title":"Environ Mol Mutagen","first-page":"299","article-title":"Increased transcriptional activity of the CYP3A4*1B promoter variant","volume":"42","author":"Amirimani B","year":"2003","unstructured":"Amirimani B, Ning B, Deitz AC,  Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 2003;42:299\u2013305."},{"key":"B62","series-title":"Clin Pharmacol Ther","first-page":"312","article-title":"The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density","volume":"85","author":"Kang YS","year":"2009","unstructured":"Kang YS, Park SY, Yim CH,  The CYP3A4*18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density. Clin Pharmacol Ther 2009;85:312\u2013318."},{"key":"B63","series-title":"J Clin Oncol","first-page":"1181","article-title":"Overcoming barriers to discovery and implementation of equitable pharmacogenomic testing in oncology","volume":"42","author":"Shriver SP","year":"2024","unstructured":"Shriver SP, Adams D, McKelvey BA,  Overcoming barriers to discovery and implementation of equitable pharmacogenomic testing in oncology. J Clin Oncol 2024;42:1181\u20131192."},{"key":"B64","series-title":"BMC Cancer","first-page":"448","article-title":"Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020","volume":"23","author":"Olivier T","year":"2023","unstructured":"Olivier T, Haslam A, Prasad V. Post-progression treatment in cancer randomized trials: a cross-sectional study of trials leading to FDA approval and published trials between 2018 and 2020. BMC Cancer 2023;23:448."},{"key":"B65","series-title":"Cancer","first-page":"2954","article-title":"A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate- resistant prostate cancer","volume":"127","author":"George DJ","year":"2021","unstructured":"George DJ, Halabi S, Heath EI,  A prospective trial of abiraterone acetate plus prednisone in Black and White men with metastatic castrate- resistant prostate cancer. Cancer 2021;127:2954\u20132965."},{"key":"B66","series-title":"NPJ Precis Oncol","first-page":"30","article-title":"Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence","volume":"9","author":"Al Abo M","year":"2025","unstructured":"Al Abo M, Foo WC, Howard LE,  Genetic ancestry concordant RNA splicing in prostate cancer involves oncogenic genes and associates with recurrence. NPJ Precis Oncol 2025;9:30."},{"key":"B67","series-title":"J Clin Oncol","first-page":"Abstract 5072","article-title":"Overall survival from PANTHER: a multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"42(","author":"George DJ","year":"2024","unstructured":"George DJ, Halabi S, Fleming MT,  Overall survival from PANTHER: a multicenter trial of apalutamide, abiraterone acetate plus prednisone in Black and White patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2024;42(Suppl):Abstract 5072."},{"key":"B68","series-title":"Nucleic Acids Res","first-page":"W452","article-title":"SIFT web server: predicting effects of amino acid substitutions on proteins","volume":"40","author":"Sim NL","year":"2012","unstructured":"Sim NL, Kumar P, Hu J,  SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012;40:W452\u2013457."},{"key":"B69","series-title":"J Clin Oncol","first-page":"Abstract 5082","article-title":"Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men","volume":"43(","author":"Freedman JA","year":"2025","unstructured":"Freedman JA, Piwarski S, Howard L,  Ceramides and response to dual secondary hormonal therapy in metastatic castration-resistant prostate cancer (mCRPC) among Black men. J Clin Oncol 2025;43(Suppl): Abstract 5082."},{"key":"B70","series-title":"Lancet Oncol","first-page":"1541","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad F","year":"2021","unstructured":"Saad F, Efstathiou E, Attard G,  Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol 2021;22:1541\u20131559."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e267002.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e267002.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e267002.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:36Z","timestamp":1783600896000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e267002.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":70,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.7002","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}